For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2. All three cohorts show separation from placebo ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Across numerous industries, the customer experience (CX) is considered more important than ever. In fact, 96% of the CX ...

Rigorous answers about the program’s effects on drug innovation are still a ways off. However, some information about ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...